Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Ashish Ramdas Nayak

Market Cap

20.03 Billion INR

Sector

Healthcare

Website

https://www.supriyalifescience.com

Description

Supriya Lifescience Ltd.

Read More

Overview

Value

28

Growth

69

Health

48

Management

61

Analyst Opinion

0

Total

52

All Scores Out Of 100

Best Features

  • Very strong cashflow and earnings growth
  • Has a low level of debt
  • Price-to-earnings ratio of 10.3 is lower than the market average (19.6x)
  • Has strong dividend growth
  • Low preportion of income is paid as dividend

Risk Factors

  • Earnings have declined recently
  • No margin of safety at their current market price

Market Peers

SUPRIYA.NS

Key Figures

PE Ratio (TTM)

10.28

Margin Of Safety (DCF)

-38.79%

Revenue Growth (5 Year Average)

18.12%

Ratings Consensus

N/A

Share Buybacks

N/A

Dividend Yeild (TTM)

N/A

Valuation

Value Score

28

  • Price-to-earnings ratio of 10.3 is lower than the market average (19.6x)
  • Estimated intrinsic-value of 154.19 INR is lower than current price ( 248.90 INR)
  • Free-cashflow-yeild of N/A is worse than the market average (4.7%)
  • Margin-of-safety of -38.79% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 231.6 INR

Current Price: 251.9 INR

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

10.28x

Free Cashflow Yeild

N/A

PE/Earnings Growth

0.45

Price/Book

3.11x

Growth

Growth Score

69

  • 5 Year Average Revenue growth of 18.12% is higher than the market average (10.97%)
  • Revenue growth has improved this yeara
  • 5 Year Average Earnings growth of 24.55% is higher than the market average (14.48%)
  • 5 Year Average Cashflow growth of 12.36% is higher than the market average (12.35%)
  • Earnings growth has slowed this year
  • Free Cashflow growth has slowed this year

Revenue Growth

18.12%

Earnings Growth

24.55%

Cashflow Growth

12.36%

Health

Health Score

48

  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Debt repayments significantly impact cashflow

Altman Z Score

N/A

Piostroski Score

N/A

Debt/Equity

0.04x

Current Assets/Liabilities

4.99x

Free Cashflow/Total Debt

N/Ax

Debt/Capital

0.06x

Dividend

Secure Dividend Score

38

  • At risk of being unsafe
  • Long term dividend payout ratio of 7.53% is considered good
  • Payout ratio (TTM) of N/A is lower than the average (40%)
  • Dividends have shown growth over the last 5 years
  • Dividend growth has been accelerating recently
  • Spending a lower percentage of their income on dividends than last 5 years
  • Dividend yeild of N/A is less than the market average (1.85%)

Dividend Yeild

N/A

Dividend Growth

11.00%

Payout Ratio (Earnings)

N/A

Payout Ratio (Cashflow)

N/A

Management

Management Score

61

  • Has not bought shares or issued new shares in the last 5 years
  • Has returned higher dividends when earnings have risen
  • Return-on-equity of 77.68% is higher than the market average (15%)
  • Return-on-capital-employed of 27.76% is higher than the market average (10%)

Average Buybacks/Dilution

N/A

Recent Buybacks/Dilution

N/A

5 Year Price Volitility

22.25%

Return On Assets

65.09%

Return On Capital Employed

27.76%

Return On Equity

77.68%

Return On Free Cashflow

1509.20%

Return On Investments

902360.58%

Analysts

Analyst Opinion

0

    SEC Filings

    Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

    Other Information

    Company Name

    Supriya Lifescience Limited

    Currency

    INR

    Beta

    0

    Vol Avg

    194380

    Ceo

    Mr. Ashish Ramdas Nayak

    Cik

    Cusip

    Exchange

    National Stock Exchange of India

    Full Time Employees

    356

    Industry

    Biotechnology

    Sector

    Healthcare

    Ipo Date

    2021-12-28

    Address

    207/208 Udyog Bhavan

    City

    Mumbai

    State

    Country

    IN

    Zip

    400063

    Phone

    91 22 4033 2727

    All financial data provided by FMP

    Noticed an error with something on our site?

    We Use Cookies